^
    Back
    Association details:
    Biomarker:IDO1 expression
    Cancer:Melanoma
    Drug:Opdivo (nivolumab) (PD1 inhibitor) +
    Yervoy (ipilimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SITC 2019
    Title:

    Identification of mRNA signatures that predict response to immunotherapy in melanoma patients

    Published date:
    11/08/2019
    Excerpt:
    Among other genes, IDO1 mRNA was also found to be significantly associated with longer PFS (P < 0.01, False discovery rate (FDR) = 0.18) and OS (P < 0.01, FDR = 0.052).